22 July 2008
Paula Olazábal joins Ysios Capital Partners as investment manager
Her appointment comes along with the new stage of the venture capital firm specialized in biotech, which is preparing the first closing of Ysios BioFund I.
Barcelona, July 22, 2008 – Ysios Capital Partners has incorporated another professional in order to complete the team to start the investment activity of Ysios BioFund I, the largest biotech venture capital firm in Spain, which is expected to make its first closing in the coming weeks. With that aim, after the recent appointment of Marc Casellas as Chief Financial Officer, the firm has incorporated Paula Olazábal as Investment Manager.
Olazábal will be in charge of analyzing the target companies of the fund from a financial point of view, as well as evaluating the investment and disinvestment opportunities, giving all the necessary support to the decision making process and collaborating in the design and structure of the transactions. The new Investment Manager will also be responsible for the financial reporting to the Investment Committee and will collaborate in the monitoring process of Ysios’ portfolio companies.
Paula Olazábal has a Degree in Business Administration from the University of the Basque Country and holds an MBA from the Instituto de Empresa. From February 2006 until her incorporation to Ysios, Olazábal was Associate in Sabadell Corporate Finance. Previously, she worked as Analyst in Nmás1 Corporate Finance and in CB Richard Ellis. During her career she has been involved in several buy and sell processes of companies in different sectors, as well as strategic consultant, being involved in several valuations and financial restructurings.
Ysios Capital Partners arose as a result of the efforts of a team of experts from the venture capital and Pharma industries, and biotech start-ups: Joël Jean-Mairet, former CEO of GLYCART Biotechnoloy AG; Julia Salaverría, former fund manager of Talde and Josep Lluís Sanfeliu, former Corporate Finance and Business Development executive of Almirall.